182 related articles for article (PubMed ID: 20454974)
21. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
Agarwala SS; Lee SJ; Yip W; Rao UN; Tarhini AA; Cohen GI; Reintgen DS; Evans TL; Brell JM; Albertini MR; Atkins MB; Dakhil SR; Conry RM; Sosman JA; Flaherty LE; Sondak VK; Carson WE; Smylie MG; Pappo AS; Kefford RF; Kirkwood JM
J Clin Oncol; 2017 Mar; 35(8):885-892. PubMed ID: 28135150
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Egberts F; Gutzmer R; Ugurel S; Becker JC; Trefzer U; Degen A; Schenck F; Frey L; Wilhelm T; Hassel JC; Schadendorf D; Livingstone E; Mauch C; Garbe C; Berking C; Rass K; Mohr P; Kaehler KC; Weichenthal M; Hauschild A
Ann Oncol; 2011 Jul; 22(7):1667-1674. PubMed ID: 21220519
[TBL] [Abstract][Full Text] [Related]
23. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
Gogas H; Bafaloukos D; Ioannovich J; Skarlos D; Polyzos A; Fountzilas G; Kalofonos HP; Aravantinos G; Tsoutsos D; Panagiotou P; Frangia K; Petrakopoulou T; Pectasides D;
Anticancer Res; 2004; 24(3b):1947-52. PubMed ID: 15274382
[TBL] [Abstract][Full Text] [Related]
24. Serum sIL-2R, TNF-alpha and IFN-gamma in alveolar echinococcosis.
Shi DZ; Li FR; Bartholomot B; Vuitton DA; Craig PS
World J Gastroenterol; 2004 Dec; 10(24):3674-6. PubMed ID: 15534930
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
Naveau S; Balian A; Degos F; Daurat V; Chevret S; Gayno S; Bastie A; Riachi G; Bartolomei-Portal I; Barange K; Moussalli J; Bailly F; Chaumet-Riffaud P; Emilie D
J Hepatol; 1999 Oct; 31(4):612-7. PubMed ID: 10551383
[TBL] [Abstract][Full Text] [Related]
26. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
28. Interleukins, TNF-alpha and beta-2M in patients with B cell chronic lymphocytic leukemia.
Mavridis AK; Tsiara S; Makis A; Chaidos A; Christou L; Seferiadis K; Bourantas KL
J Exp Clin Cancer Res; 1998 Dec; 17(4):445-8. PubMed ID: 10089066
[TBL] [Abstract][Full Text] [Related]
29. Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.
Szymona K; Zdzisińska B; Karakuła-Juchnowicz H; Kocki T; Kandefer-Szerszeń M; Flis M; Rosa W; Urbańska EM
Neurotox Res; 2017 Jul; 32(1):17-26. PubMed ID: 28275903
[TBL] [Abstract][Full Text] [Related]
30. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.
Nukui A; Masuda A; Abe H; Arai K; Yoshida KI; Kamai T
BMC Cancer; 2017 May; 17(1):372. PubMed ID: 28545581
[TBL] [Abstract][Full Text] [Related]
31. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.
Evereklioglu C; Er H; Türköz Y; Cekmen M
Mediators Inflamm; 2002 Apr; 11(2):87-93. PubMed ID: 12061429
[TBL] [Abstract][Full Text] [Related]
32. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy.
Simsek H; Kadayifci A
J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984
[TBL] [Abstract][Full Text] [Related]
33. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
34. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.
Erbağci AB; Herken H; Köylüoglu O; Yilmaz N; Tarakçioglu M
Mediators Inflamm; 2001 Jun; 10(3):109-15. PubMed ID: 11545247
[TBL] [Abstract][Full Text] [Related]
35. Evaluation on serum 2'-5'oligoadenylate synthetase (2'-5'oligoAS) and beta 2 microglobulin (B2M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A.
Martinetti A; Seregni E; Belli F; Mazzocchi A; Agresti R; Cascinelli N; Greco M; Bombardieri E
Anticancer Res; 1998; 18(3B):2027-30. PubMed ID: 9677461
[TBL] [Abstract][Full Text] [Related]
36. Cytokine serum levels in patients with cervical intraepithelial neoplasia grade II-III treated with intralesional interferon-α 2b.
Misson DR; Abdalla DR; Borges AM; Shimba DS; Adad SJ; Michelin MA; Murta EF
Tumori; 2011; 97(5):578-84. PubMed ID: 22158487
[TBL] [Abstract][Full Text] [Related]
37. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
Agarwala SS
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
[TBL] [Abstract][Full Text] [Related]
39. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
40. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
